Nathalie Bernard-Marissal is a neuroscientist who has devoted the last 15 years of her research to two rare neurological diseases: amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth disease (CMT). During her PhD at the University of Aix-Marseille and her postdoctoral training at the University of Lausanne and the Swiss Federal Institute of Technology Lausanne (EPFL), she developed a strong expertise in various mouse models of ALS and CMT, including both axonal and demyelinating forms. This has enabled her to discover new pathological mechanisms and test innovative therapeutic approaches. Since 2022, she is a group leader at Marseille Medical Genetics (Translational neuromyology team). Her research primarily focuses on deciphering the role of organelle dysfunction to reveal new molecular targets in CMT2A, as well as in a hereditary motor neuropathy and an ALS subtype linked to SIGMAR1 mutations. Concurrently, she is developing pharmacological and gene therapy strategies for CMT2A and CMT4H. She sits on the NeuroSchool committee of the neuroscience doctoral program at Aix-Marseille University and on the scientific and medical council of CMT France.

ORCID: **0000-0002-2160-2612**